Select Publications

Atkins MB et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18. Abstract

Escudier B et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. Abstract

Hudes G et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81. Abstract

Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24. Abstract

Motzer RJ et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006a;24(1):16-24. Abstract

Motzer RJ et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006b;295(21):2516-24. Abstract

Ratain MJ et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505- 12. Abstract

Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. Abstract

 

 

 

 

 

 

 

 

 

 

 

Home

Editor
Neil Love, MD

Interviews

Robert J Motzer, MD
- Select publications

Daniel J George, MD
- Select publications

Robert J Amato, DO
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office